Early results for a potential HIV vaccine are promising. The vaccine
elicited a vital part of the human immune response in 97% of its
participants.
The study was a tiny, phase 1 trial for an HIV vaccine created from a
synthetic version of a naturally occurring protein on the virus. Completing
immunity to HIV is thought to require the production of “broadly
neutralizing antibodies,” and this article was created to prime the body to
do just that.
Because the HIV virus continually undergoes mutations, immunity must be
conferred by antibodies recognizing a wide variety of HIV subtypes.
elicited a vital part of the human immune response in 97% of its
participants.
The study was a tiny, phase 1 trial for an HIV vaccine created from a
synthetic version of a naturally occurring protein on the virus. Completing
immunity to HIV is thought to require the production of “broadly
neutralizing antibodies,” and this article was created to prime the body to
do just that.
Because the HIV virus continually undergoes mutations, immunity must be
conferred by antibodies recognizing a wide variety of HIV subtypes.
